<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27046319</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>08</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2016</Year>
        <Month>04</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1555-2101</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>77</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of clinical psychiatry</Title>
          <ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Neurobiology of depression and mechanism of action of depression treatments.</ArticleTitle>
        <Pagination>
          <StartPage>e319</StartPage>
          <MedlinePgn>e319</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.13097tx3c</ELocationID>
        <Abstract>
          <AbstractText>Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), may alleviate depressive symptoms but also leave residual symptoms. The mechanism of action of SSRIs increases serotonin (5-HT) activity but decreases norepinephrine (NE) and dopamine (DA) activity. By engaging additional targets (eg, NE, DA) along with 5-HT, clinicians may help patients with residual symptoms and treatment-resistant depression. Dual-acting agents and combination strategies can be used to target specific symptoms or block/activate specific receptors for broader therapeutic benefits. Clinicians who understand the mechanism of action of antidepressants can switch or combine agents as needed to help patients achieve complete remission.</AbstractText>
          <CopyrightInformation>Â© Copyright 2016 Physicians Postgraduate Press, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Blier</LastName>
            <ForeName>Pierre</ForeName>
            <Initials>P</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Clin Psychiatry</MedlineTA>
        <NlmUniqueID>7801243</NlmUniqueID>
        <ISSNLinking>0160-6689</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D059331" MajorTopicYN="N">Adrenergic Neurons</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059290" MajorTopicYN="N">Dopaminergic Neurons</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059326" MajorTopicYN="N">Serotonergic Neurons</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27046319</ArticleId>
        <ArticleId IdType="doi">10.4088/JCP.13097tx3c</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
